We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the best-performing stocks on Friday. Illumina rallied for a second day on Friday, ...
Illumina (ILMN) has returned to profitability, reporting high quality earnings and trading at $123.54 per share, which is below its estimated fair value of $166.88. The company is forecasting EPS ...
Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ban. The $1.08 billion it brought in for the third quarter was, however, ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Illumina Inc. (ILMN) on Thursday reported third-quarter profit of $150 million. The San Diego-based company said it had net income of 98 cents per share. Earnings, ...
"Illumina has inflicted substantial harm on Element, resulting in lost sales, diminished market share, and reduced profits," counsel for DNA-sequencing company Element Biosciences Inc. alleged in an ...
Sept 22 (Reuters) - Life sciences company Element Biosciences sued Illumina (ILMN.O), opens new tab on Monday in separate cases in federal courts in California and ...
Illumina has begun rolling out its protein research platform, powered in part by tech from SomaLogic, which the DNA sequencing giant signed up to buy out a few months ago after years of collaborative ...
At the Crossroads: Illumina Settlement Reflects the Intersection of Cybersecurity and Healthcare Law
On July 31, the U.S. Department of Justice (DOJ) announced a settlement in United States ex rel. Lenore v. Illumina, Inc, the first case in which underlying cybersecurity issues formed the basis of a ...
In the last three months, 11 analysts have published ratings on Illumina (NASDAQ:ILMN), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...
Illumina this month named Mark Field as its next Chief Information Officer, adding a veteran technology and R&D executive to its leadership team as the DNA sequencing giant navigates the next wave of ...
The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback